Aldosterone Renin Ratio (ARR) Test to Increase Case-detection of Primary Aldosteronism (PA) (NCT05757076) | Clinical Trial Compass
CompletedNot Applicable
Aldosterone Renin Ratio (ARR) Test to Increase Case-detection of Primary Aldosteronism (PA)
United States53 participantsStarted 2023-05-02
Plain-language summary
The mission of this project is to increase the detection of Primary Aldosteronism (PA), the most common cause of secondary hypertension, which can either be cured surgically or treated with targeted medications.
Who can participate
Age range18 Years – 65 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Consent to participate in the study
* Participants limited to subjects in the CCF
* Age between and inclusive of 18 and 65 years of age
* No gender exclusion
* Patients diagnosed with Essential Hypertension by ICD-10 code on at least two occasions in the previous six months, even if not on medications for hypertension
* Patients on a single anti-hypertensive medication for at least six months with the diagnosis of hypertension
Exclusion Criteria:
* Those on a mineralocorticoid antagonist therapy (spironolactone, eplerenone)
* Those with a documented diagnosis of primary aldosteronism or primary hyperaldosteronism
* Those with a diagnosis of secondary hyperaldosteronism
* Those with a diagnosis of heart failure, renal artery stenosis, cirrhosis, ascites, cor pulmonale.
* Pregnancy status (verbal)
What they're measuring
1
Percentage of patients with Primary Aldosteronism (PA) that were missed.